Orloff departs FDA
Executive Summary
Metabolic & Endocrine Disorders Division Director David Orloff will step down Dec. 30 after 11 years with FDA to become the medical director of contract research organization Medpace, Inc. Orloff announced his resignation Nov. 29. Division Deputy Director Mary Parks will take over as acting director Jan. 1 until a permanent successor is named. Orloff, who oversaw FDA's review of Bristol-Myers Squibb's Pargluva, is one of several top officials to resign since summer, following the departures of Commissioner Lester Crawford and Office of Women's Health Director Susan Wood...
You may also be interested in...
Division of Metabolic & Endocrine Products director
Acting Division of Metabolic & Endocrine Products Director Mary Parks will hold the permanent position as of Aug. 6. Parks, former ODE II division deputy director and team leader for lipid-lowering drugs, was promoted to director following the departure of David Orloff Jan. 1 (1The Pink Sheet" Dec. 12, 2005, In Brief)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.